First Approval for a New Immune Checkpoint Inhibitor | Research | AACR
The FDA approved cosibelimab-ipdl for locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) not treatable by surgery or radiation. It's a PD-L1 inhibitor, causing fewer high-grade immune-related adverse effects than PD-1 inhibitors. The approval was based on a clinical trial showing 47-48% response rates with median response durations of 17.7 months for locally advanced disease.
Related Clinical Trials
Highlighted Terms
Related News
The FDA approved cosibelimab-ipdl for locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) not treatable by surgery or radiation. It's a PD-L1 inhibitor, causing fewer high-grade immune-related adverse effects than PD-1 inhibitors. The approval was based on a clinical trial showing 47-48% response rates with median response durations of 17.7 months for locally advanced disease.